ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2022

1:00PM-3:00PM: Abstract Number: L08

Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders

(L07–L17) Late-Breaking Abstract Poster

1:00PM-3:00PM: Abstract Number: 2091

Burden and Incidence of Multimorbidity in Systemic Lupus Erythematosus in a Community Population-Based Cohort: The Lupus Midwest Network

SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

1:00PM-3:00PM: Abstract Number: 1952

Burden of Disease in Refractory Rheumatoid Arthritis

RA – Diagnosis, Manifestations, and Outcomes Poster IV

1:00PM-3:00PM: Abstract Number: 1992

Burden of Pain for Patients in the CorEvitasTM Rheumatoid Arthritis Registry

RA – Treatment Poster IV

1:00PM-3:00PM: Abstract Number: 1690

Butyric Acid Suppresses Migration of Human Monocyte Derived Dendritc Cell by Inhibiting Actin Polymerization via mDia1 Inhibition

Innate Immunity Poster: Basic and Translational Science

1:00PM-3:00PM: Abstract Number: 1819

Calcium Pyrophosphate Deposition Disease Is Associated with an Increased Prevalence of Nephrolithiasis

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1834

Canakinumab Treatment in Familial Mediterranean Fever Patients with Colchicine Resistance: A Single-center Study

Miscellaneous Rheumatic and Inflammatory Diseases Poster III

1:00PM-3:00PM: Abstract Number: 1752

Cancer Risk in Patients with Rheumatic Diseases Exposed to Different Biologic and Targeted Synthetic DMARDs in Real World Clinical Practice: Data from BIOBADASER

Epidemiology and Public Health Poster III

1:00PM-3:00PM: Abstract Number: 2169

Cardiac Rhythm and Conduction Abnormalities in Systemic Sclerosis-meta-analysis

Systemic Sclerosis and Related Disorders – Clinical Poster III

1:00PM-3:00PM: Abstract Number: 1846

Cardiac Sarcoidosis: An Underdiagnosed, Life-threatening yet Treatable Disease

Miscellaneous Rheumatic and Inflammatory Diseases Poster III

1:00PM-3:00PM: Abstract Number: 2001

Cardiovascular Risk Factors and Therapeutic Outcome in Rheumatoid Arthritis – Real World Data

RA – Treatment Poster IV

1:00PM-3:00PM: Abstract Number: 1710

CCL2 Drives Interferon-enhanced Monocytosis in UV-mediated Skin Injury in Murine Lupus

SLE – Animal Models Poster

1:00PM-3:00PM: Abstract Number: 1993

Changes in Omega-6- and Omega-3-Derived Bioactive Lipids in Response to an Anti-Inflammatory Dietary Intervention

RA – Treatment Poster IV

1:00PM-3:00PM: Abstract Number: 2108

Changes in Serum Cytokines by Week 24 Correlate with Long-Term Efficacy of Guselkumab Through Two Years in Bio-Naïve Adults with PsA

Spondyloarthritis Including PsA – Treatment Poster III: PsA

1:00PM-3:00PM: Abstract Number: 1747

Changes in the Number and Phenotype of Citrullinated-Antigen Specific T Cells Correlate with Treatment Outcome in Seropositive Rheumatoid Arthritis

T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

«Previous Page
1
…
8
9
10
11
12
…
45
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].